Risks of Intravenous Injection of Live Stem Cells

Clarification Statement

I hereby clarify that the intravenous injection of live stem cells poses serious medical risks due to uncontrolled genetic activity, vascular complications, and insufficient reproducibility and standardization.

1. Genetic Instability and Tumor Formation

Live stem cells are closely associated with Chromosome 13 (GAS6) and Chromosome 19 (AXL) gene pathways. When injected into the body, these genes may become uncontrollable, leading to abnormal cellular proliferation. This uncontrolled growth can result in tumor formation and increase the risk of malignant transformation.

2. Vascular Occlusion and Sclerosis

Stem cells introduced directly into the bloodstream can aggregate or adhere to vessel walls, causing vascular sclerosis and occlusion. Such blockages may lead to severe complications, including heart attack and stroke, due to impaired blood flow.

3. Lack of Reproducibility, Standardization, and Safety

Current intravenous stem cell injection practices lack scientific reproducibility and clinical standardization. Procedures vary widely without consistent protocols or validated outcomes. Furthermore, safety verification is insufficient, and no international medical authority has approved this method. As a result, patients may face unpredictable and potentially life-threatening consequences.

4. Conclusion

The intravenous administration of live stem cells is unsafe because it increases the risk of tumor development through uncontrolled gene expression (Chromosomes 13 and 19) and promotes vascular occlusion through sclerosis. In addition, the absence of reproducibility, standardization, and verified safety further underscores the danger of this procedure.

Stem cell therapy must only be performed under scientifically validated, standardized, and safety-assured conditions, prioritizing patient health and ethical medical practice.

---